Background Treatment with systemic corticosteroids in patients with acute exacerbations of
chronic obstructive pulmonary disease (COPD) is associated with debilitating adverse …

Background Little is known about the impact of exacerbations on COPD progression or
whether inhaled corticosteroid (ICS) use and blood eosinophil count (BEC) affect …

Background Most patients with chronic obstructive pulmonary disease (COPD) receive
inhaled long-acting bronchodilators and inhaled corticosteroids. Conventional meta …

Abstract Background Clinically Important Deterioration (CID) is a novel composite measure
to assess treatment effect in chronic obstructive pulmonary disease (COPD). We examined …

Introduction: The aim was to investigate how the pattern of pharmacological treatment in
Swedish patients with chronic obstructive pulmonary disease (COPD) has changed over a …

Chronic obstructive pulmonary disease (COPD) is a common, complex, and heterogeneous
disorder that is responsible for substantial and growing morbidity, mortality, and health-care …

In chronic obstructive pulmonary disease (COPD), treatment with inhaled corticosteroids
(ICSs) in combination with long acting beta-2-agonists (LABA) or LABA/long-acting …

Chronic obstructive pulmonary disease (COPD) is a major cause of ill health and medical
expenditure worldwide. Despite recent increases in the knowledge about the nature of the …

Introduction: Current guidelines recommend the use of inhaled long-acting bronchodilators,
inhaled corticosteroids (ICSs) and their combinations for maintenance treatment of moderate …

Chronic obstructive pulmonary disease (COPD) has a 3-year mortality rate up to 37%, 2–6
times higher than the general population. We present evidence supporting pharmacological …